ARTICLE | Clinical News
Pramlintide/Metreleptin: Extension study data
March 1, 2010 8:00 AM UTC
Data from a 24-week extension of a 28-week Phase II trial in about 275 patients showed that patients who continued treatment with pramlintide/metreleptin for a total of 52 weeks demonstrated sustained...